NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Jeffrey A. Meckler to the Board of Directors as a fourth independent director.
“Jeff brings to our board of directors broad industry experience ranging from early stage to large pharmaceutical,” said Stephen Aselage, Chief Executive Officer of Retrophin. “His insights will help advance the pipeline and grow the company through opportunistic business development opportunities.”
Help employers find you! Check out all the jobs and post your resume.
